Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Endocrinology · Prolactinoma

Life Beyond Diagnosis: Long-Term Care and Well-Being

At a Glance

Long-term care for a prolactinoma involves routine blood tests and MRIs to monitor tumor size and prolactin levels. Many patients achieve normal hormone levels and can eventually safely stop their medication, though regular monitoring for side effects like impulse control disorders is essential.

Life with a prolactinoma is often a marathon, not a sprint. Because these tumors are benign and highly responsive to treatment, the focus eventually shifts from “fighting a tumor” to long-term health maintenance and monitoring [1]. With the right care, most patients can expect to live a normal, healthy life.

The Monitoring Routine

Once your prolactin levels have stabilized and the tumor has begun to shrink, your “new normal” will involve a routine monitoring schedule.

  • Blood Tests: You will have regular blood draws to check your serum prolactin levels. Initially, these may be every few months, but once stable, they may only be needed once or twice a year [2][3].
  • MRI Scans: Periodic imaging is used to ensure the tumor remains stable or continues to shrink. The frequency depends on your tumor size—macroprolactinomas typically require more frequent imaging than microprolactinomas [4].

Monitoring for “Impulse” Side Effects

While dopamine agonists like cabergoline are excellent at treating the tumor, they can affect the brain’s reward system [5]. A medically recognized side effect is the development of Impulse Control Disorders (ICDs) [6].

  • What to watch for: New or excessive urges to spend money, gamble, engage in hypersexuality, or exhibit other impulsive behaviors that are “out of character” for you [7][8].
  • Who is at risk: Men and those on higher doses of medication may be at a slightly higher risk [9][10].
  • The solution: These behaviors are usually reversible. If you or your family notice these changes, your doctor can often manage them by reducing your dose or switching treatments [11].

The Goal of “Medication Withdrawal”

One of the most encouraging aspects of prolactinoma treatment is that the medication may not be permanent.

  • Candidacy: You may be a candidate to trial stopping your medication if you have been on it for at least two years, your prolactin levels are consistently normal, and your tumor has shrunk significantly (or disappeared from the MRI) [12][13].
  • Success Rates: Some patients remain in “remission” (normal levels without pills) for years, while others may eventually need to restart treatment if their levels begin to rise again [14][12].

Protecting Your Long-Term Health

Managing your prolactin isn’t just about the tumor; it’s about protecting your whole body.

  • Lifestyle and Diet: No specific diets or extreme lifestyle changes are required to manage a prolactinoma. The medication does the heavy lifting [15]. Maintaining a generally healthy lifestyle is always recommended, but do not feel pressured to “fix” the tumor with supplements or diets.
  • Bone Health: Chronic high prolactin suppresses the sex hormones (estrogen and testosterone) that keep your bones strong. This can lead to osteoporosis or bone loss, particularly in the spine and hips [16][17]. Treating the prolactinoma is the best way to stop this bone loss [18].
  • Metabolic Health: High prolactin is also linked to metabolic issues like high cholesterol and insulin resistance [19]. Bringing your levels into a healthy range can improve your metabolic profile and potentially reduce cardiovascular risks [20][21].

A Note on Quality of Life

Research shows that as your hormone levels normalize, your overall quality of life typically returns to near-normal levels [22]. While the journey involves regular doctor visits and lab work, the goal is to ensure the condition is a “background” part of your life rather than the focus of it.

Back to Home

Common questions in this guide

How often will I need blood tests and MRIs for my prolactinoma?
Once your prolactin levels are stable, you may only need blood tests once or twice a year. MRI frequency depends on the size of your tumor, with larger tumors requiring more frequent imaging.
What are the behavioral side effects of cabergoline?
Dopamine agonists like cabergoline can sometimes cause impulse control disorders. You or your family should watch for new, out-of-character urges such as excessive spending, gambling, or hypersexuality.
Can I ever stop taking medication for a prolactinoma?
You may be a candidate to stop medication if you have been on it for at least two years, your prolactin levels are consistently normal, and your tumor has significantly shrunk. Many patients successfully achieve long-term remission.
Does a prolactinoma affect my bone health?
Yes, chronic high prolactin can suppress sex hormones like estrogen and testosterone, which are essential for strong bones. This can lead to bone loss or osteoporosis, making it important to effectively treat the tumor.
Will I need to follow a special diet to manage my prolactinoma?
No specific diets or extreme lifestyle changes are required to manage a prolactinoma. Your medication is the primary treatment, though maintaining a generally healthy lifestyle is always recommended for your overall well-being.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How long must my prolactin levels be normal before we consider tapering or stopping my medication?
  2. 2.What specific behavioral changes or 'impulse' shifts should my family and I watch for while I'm on cabergoline?
  3. 3.Given my history, do I need a bone density scan (DEXA) to check for osteoporosis?
  4. 4.How frequently will we be doing blood tests and MRIs once my levels have stabilized?
  5. 5.If I experience psychiatric side effects, what is the 'backup plan' for managing my tumor?
  6. 6.What are the signs that my tumor might be recurring if we decide to trial a medication withdrawal?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    The Role of Dopamine Agonists in Pituitary Adenomas.

    Giraldi EA, Ioachimescu AG

    Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

    PMID: 32741482
  2. 2

    A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

    Mishra R, Konar SK, Shrivastava A, et al.

    Indian journal of endocrinology and metabolism 2021; (25(6)):493-506 doi:10.4103/ijem.ijem_338_21.

    PMID: 35355923
  3. 3

    Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case.

    Gamboa NT, Wilkerson C, Kundu B, et al.

    Journal of neurosurgery. Case lessons 2023; (5(3)).

    PMID: 36647250
  4. 4

    The Role of Surgery in the Management of Prolactinomas.

    Donoho DA, Laws ER

    Neurosurgery clinics of North America 2019; (30(4)):509-514 doi:10.1016/j.nec.2019.05.010.

    PMID: 31471058
  5. 5

    Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia.

    Zerbinati L, Cristilli G, Valier B, et al.

    Pituitary 2026; (29(3)).

    PMID: 42149330
  6. 6

    Impulse Control Disorders in Southern Iraqi Patients Medicated With Cabergoline for Prolactinoma.

    Mohammad MM, Alidrisi HA, Mansour AA

    Cureus 2024; (16(4)):e58516 doi:10.7759/cureus.58516.

    PMID: 38957818
  7. 7

    The risks of medical treatment of prolactinoma.

    Castinetti F, Albarel F, Amodru V, et al.

    Annales d'endocrinologie 2021; (82(1)):15-19 doi:10.1016/j.ando.2020.12.008.

    PMID: 33373604
  8. 8

    Increased impulsivity and higher odds of compulsive shopping among cabergoline-treated patients with prolactinoma: a case-control study.

    Daniel KB, Glezer A, de Queiroz NL, et al.

    Pituitary 2026; (29(4)).

    PMID: 42496764
  9. 9

    Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic.

    Lydiatt M, Grissom B, Givens J, et al.

    Journal of psychiatric research 2026; (195()):105-112 doi:10.1016/j.jpsychires.2026.01.041.

    PMID: 41619686
  10. 10

    Impulse control disorders in Parkinson's disease: a hard-turning point.

    Martinez-Castrillo JC

    Journal of neurology, neurosurgery, and psychiatry 2019; (90(1)):2 doi:10.1136/jnnp-2018-319375.

    PMID: 30361297
  11. 11

    Developments in impulse control behaviours of Parkinson's disease.

    Zurowski M, O'Brien JD

    Current opinion in neurology 2015; (28(4)):387-92 doi:10.1097/WCO.0000000000000209.

    PMID: 26110803
  12. 12

    Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.

    Xia MY, Lou XH, Lin SJ, Wu ZB

    Endocrine 2018; (59(1)):50-61 doi:10.1007/s12020-017-1444-9.

    PMID: 29043560
  13. 13

    Best candidates for dopamine agonist withdrawal in patients with prolactinomas.

    Ji MJ, Kim JH, Lee JH, et al.

    Pituitary 2017; (20(5)):578-584 doi:10.1007/s11102-017-0820-z.

    PMID: 28710724
  14. 14

    Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.

    Santharam S, Fountas A, Tampourlou M, et al.

    Clinical endocrinology 2018; (89(3)):346-353 doi:10.1111/cen.13765.

    PMID: 29894000
  15. 15

    Decrease of Proliferative Potential and Vascular Density of Giant Prolactinoma in Patients Treated with Cabergoline.

    Astaf'eva L, Shishkina L, Kalinin P, et al.

    Asian journal of neurosurgery 2020; (15(2)):385-390 doi:10.4103/ajns.AJNS_16_20.

    PMID: 32656137
  16. 16

    Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis.

    Nagendra L, Dutta D, Mondal S, et al.

    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2024; (27(1)):101453 doi:10.1016/j.jocd.2023.101453.

    PMID: 38064881
  17. 17

    Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.

    Andereggen L, Frey J, Andres RH, et al.

    Scientific reports 2021; (11(1)):5122 doi:10.1038/s41598-021-84606-x.

    PMID: 33664388
  18. 18

    Successful Improvement of Metabolic Disorders, Including Osteopenia, by a Dopamine Agonist in a Male Patient with Macro-Prolactinoma.

    Takeno A, Yamamoto M, Okazaki K, et al.

    The American journal of case reports 2016; (17()):160-4 doi:10.12659/ajcr.894712.

    PMID: 26971354
  19. 19

    Hyperprolactinemia alters insulin resistance profiles in overweight males.

    Rashed HM, El-Ghlban S, Mahfouz MK, Marie YMA

    Endocrine regulations 2025; (59(1)):160-166 doi:10.2478/enr-2025-0018.

    PMID: 41217054
  20. 20

    Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.

    Aboelnaga MM, Eladawy EH, Elshafei MM, et al.

    Endocrine, metabolic & immune disorders drug targets 2019; (19(4)):511-518 doi:10.2174/1871530319666190219103812.

    PMID: 30806330
  21. 21

    Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.

    Schwetz V, Librizzi R, Trummer C, et al.

    Metabolic brain disease 2017; (32(1)):155-161 doi:10.1007/s11011-016-9882-2.

    PMID: 27525431
  22. 22

    Quality of life in Prolactinoma: A systematic review.

    Castle-Kirszbaum M, Biermasz N, Kam J, Goldschlager T

    Pituitary 2024; (27(3)):239-247 doi:10.1007/s11102-024-01392-1.

    PMID: 38656635

This page provides information on long-term management of prolactinomas for educational purposes only. Always consult your endocrinologist regarding medication changes or monitoring schedules.

Get notified when new evidence is published on prolactin producing pituitary tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.